Last reviewed · How we verify

Jacob Pontoppidan Thyssen — Portfolio Competitive Intelligence Brief

Jacob Pontoppidan Thyssen pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Elocon 0.1 % Topical Cream Elocon 0.1 % Topical Cream marketed Topical corticosteroid (Class III/IV potency) Glucocorticoid receptor Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Fougera Pharmaceuticals Inc. · 1 shared drug class
  3. GlaxoSmithKline · 1 shared drug class
  4. Peking Union Medical College Hospital · 1 shared drug class
  5. Pfizer · 1 shared drug class
  6. Wake Forest University Health Sciences · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Jacob Pontoppidan Thyssen:

Cite this brief

Drug Landscape (2026). Jacob Pontoppidan Thyssen — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jacob-pontoppidan-thyssen. Accessed 2026-05-16.

Related